# Pfizer Inc. (PFE)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $149.51B  
**Price:** $26.17 (+2.23%)

> Pfizer Inc. is a leading biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells prescription drugs and vaccines worldwide. Operating in segments including Biopharma, PC1, and Pfizer Ignite, it focuses on key therapeutic areas such as oncology, cardiology, immunology, and infectious diseases. Notable products in its portfolio include the pneumococcal vaccine Prevnar 13, cardiovascular treatments like Vyndaqel and Eliquis, and oncology drug Padcev. Pfizer Inc. serves markets in the United States and internationally, with significant contributions from emerging markets representing a substantial portion of international sales. The company addresses critical health needs through innovative medicines that treat chronic and acute conditions, playing a vital role in global healthcare delivery. Founded in 1849 and headquartered in New York, New York, Pfizer Inc. maintains a broad presence in the pharmaceutical industry, supporting patients, healthcare providers, and public health initiatives across diverse regions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $62.58B | $46.51B | — | $7.77B | $1.36 |
| 2024 | $63.63B | $45.78B | — | $8.03B | $1.41 |
| 2023 | $50.91B | $25.96B | — | $2.12B | $0.37 |
| 2022 | $91.79B | $57.45B | — | $31.37B | $5.47 |
| 2021 | $73.64B | $42.81B | — | $21.98B | $3.85 |
| 2020 | $41.65B | $33.17B | — | $9.16B | $1.63 |
| 2019 | $40.91B | $32.85B | — | $16.03B | $2.82 |
| 2018 | $40.83B | $31.84B | — | $11.15B | $1.87 |
| 2017 | $52.55B | $41.32B | — | $21.31B | $3.52 |
| 2016 | $52.82B | $40.50B | — | $7.21B | $1.17 |
| 2013 | $51.58B | $42.00B | — | $22.00B | $3.19 |
| 2012 | $54.66B | $44.84B | — | $14.57B | $1.94 |
| 2011 | $61.03B | $48.53B | — | $10.01B | $1.27 |
| 2010 | $65.17B | $50.38B | — | $8.26B | $1.02 |
| 2009 | $49.27B | $40.81B | — | $8.63B | $1.23 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $208.16B | $121.39B | $86.48B | $1.14B | $61.64B |
| 2024 | $213.40B | $124.90B | $88.20B | $1.04B | $57.41B |
| 2023 | $226.50B | $137.21B | $89.01B | $2.85B | $61.54B |
| 2022 | $197.21B | $101.29B | $95.66B | $416M | $32.88B |
| 2021 | $181.48B | $104.01B | $77.20B | $1.94B | $36.20B |
| 2020 | $154.23B | $90.76B | $63.24B | $1.79B | $4.00B |
| 2019 | $167.59B | $104.15B | $63.14B | $1.12B | $35.95B |
| 2018 | $159.42B | $95.66B | $63.41B | $1.14B | $32.91B |
| 2017 | $171.80B | $100.14B | $71.31B | $1.34B | $33.54B |
| 2016 | $171.62B | $111.78B | $59.54B | $2.60B | $31.40B |
| 2013 | $172.10B | $95.48B | $76.31B | $2.18B | $30.46B |
| 2012 | $185.80B | $104.12B | $81.26B | $10.08B | $31.04B |
| 2011 | $188.00B | $105.38B | $82.19B | $3.18B | $34.93B |
| 2010 | $195.01B | $106.75B | $87.81B | $1.74B | $38.41B |
| 2009 | $212.95B | $122.50B | $90.01B | $1.98B | $43.19B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $11.70B | $2.63B | $9.07B |
| 2024 | $12.74B | $2.91B | $9.84B |
| 2023 | $8.70B | $3.91B | $4.79B |
| 2022 | $29.27B | $3.24B | $26.03B |
| 2021 | $32.58B | $2.71B | $29.87B |
| 2020 | $14.40B | $2.23B | $12.18B |
| 2019 | $12.59B | $2.05B | $10.54B |
| 2018 | $15.83B | $1.98B | $13.84B |
| 2017 | $16.80B | $1.96B | $14.85B |
| 2016 | $16.19B | $1.82B | $14.37B |
| 2015 | $14.69B | $1.40B | $13.29B |
| 2014 | $17.08B | $1.20B | $15.88B |
| 2013 | $17.68B | $1.21B | $16.48B |
| 2012 | $16.75B | $1.33B | $15.42B |
| 2011 | $20.24B | $1.66B | $18.58B |

Source: [CompaniesByCap](https://companiesbycap.com/company/PFE)